Cargando…

Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours

PURPOSE: The aim of the project was to evaluate intra-CSF etoposide administration in a palliative setting for children and young people with relapsed/refractory central nervous system (CNS) tumours, with the primary endpoints being overall survival and progression-free survival time. A safety endpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butler, Anna, Meijer, Lisethe, Liu, Jo-Fen, Chohan, Manjit, Jalloh, Ibrahim, Macarthur, Donald, Parr, Margaret, Wilne, Sophie, Wilson, Shaun, Walker, David, Grundy, Richard, Dandapani, Madhumita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227148/ https://www.ncbi.nlm.nih.gov/pubmed/36949251 http://dx.doi.org/10.1007/s00381-023-05872-w

Ejemplares similares

Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)
por: Apps, John R, et al.
Publicado: (2022)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

RARE-03 CENTRAL NERVOUS SYSTEM TUMORS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1, A COHORT FROM A NATIONAL PEDIATRIC ONCOLOGY CENTER
por: Vandenput, Kim, et al.
Publicado: (2021)

The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review
por: Main, Caroline, et al.
Publicado: (2016)

Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors
por: Servante, Juliette, et al.
Publicado: (2018)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

TBIO-14. CHARACTERISATION OF THE ARGININE PATHWAY ENZYMES IN PAEDIATRIC BRAIN TUMOURS TO DETERMINE SUSCEPTIBILITY TO THERAPEUTIC ARGININE DEPLETION
por: Bishop, Eleanor, et al.
Publicado: (2020)

Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
por: Cowie, F. J., et al.
Publicado: (1995)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse
por: Im, Annie, et al.
Publicado: (2016)

The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
por: Tomassetti, Sarah, et al.
Publicado: (2019)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma
por: Zhu, Zhijuan, et al.
Publicado: (2022)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Whole‐body MRI for cancer surveillance in ataxia–telangiectasia: A qualitative study of the perspectives of people affected by A‐T and their families
por: Neves, Renata, et al.
Publicado: (2023)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Refractory Choriocarcinoma: Complete Response With Oral Etoposide
por: Dhanushkodi, Manikandan, et al.
Publicado: (2016)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
por: Wu, Chunsheng, et al.
Publicado: (2020)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

An unusual headache: CSF negative APML relapse in the brain
por: Quinn, Thomas, et al.
Publicado: (2020)

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Molecular mechanisms of etoposide
por: Montecucco, Alessandra, et al.
Publicado: (2015)

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
por: Seymour, L. K., et al.
Publicado: (1994)

Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin’s lymphoma patients with a poor performance status or comorbidity
por: LIN, XUEDE, et al.
Publicado: (2014)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer
por: Baur, M, et al.
Publicado: (2005)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma
por: Ding, Yi, et al.
Publicado: (2023)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
por: Seymour, M. T., et al.
Publicado: (1994)

Successful combination chemotherapy involving clofarabine, cyclophosphamide, and etoposide for pediatric relapsed acute myeloid leukemia: A case report
por: Fujita, Sachio, et al.
Publicado: (2021)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fpiufpk42ij8qadqpuisql845n